Astria Therapeutics (NASDAQ:ATXS) Releases Quarterly Earnings Results

Key Points

• Astria Therapeutics reported a quarterly loss of $0.57 per share, exceeding analyst expectations by $0.04.
• The company's stock price is currently at $6.65 with a market capitalization of $375.26 million.
• Analysts have a consensus rating of "Buy" for Astria Therapeutics, with a target price averaging $29.00.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04, Zacks reports.

Astria Therapeutics Trading Up 1.3%

Shares of ATXS traded up $0.09 during trading hours on Friday, reaching $6.85. 406,491 shares of the company traded hands, compared to its average volume of 248,389. The firm has a market cap of $386.61 million, a price-to-earnings ratio of -3.41 and a beta of 0.48. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.92. The stock's fifty day moving average price is $6.23 and its 200 day moving average price is $5.74.

Analyst Ratings Changes

A number of research analysts recently weighed in on ATXS shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Wednesday. JMP Securities raised their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a report on Wednesday. Finally, Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $29.00.

Institutional Trading of Astria Therapeutics

A number of large investors have recently made changes to their positions in ATXS. American Century Companies Inc. lifted its stake in Astria Therapeutics by 8.3% in the second quarter. American Century Companies Inc. now owns 56,442 shares of the biotechnology company's stock worth $303,000 after acquiring an additional 4,335 shares during the period. Bank of America Corp DE lifted its stake in Astria Therapeutics by 24.9% in the second quarter. Bank of America Corp DE now owns 49,628 shares of the biotechnology company's stock worth $266,000 after acquiring an additional 9,881 shares during the period. Rhumbline Advisers lifted its stake in Astria Therapeutics by 18.2% in the second quarter. Rhumbline Advisers now owns 75,674 shares of the biotechnology company's stock worth $406,000 after acquiring an additional 11,663 shares during the period. Raymond James Financial Inc. lifted its stake in Astria Therapeutics by 15.5% in the second quarter. Raymond James Financial Inc. now owns 90,583 shares of the biotechnology company's stock worth $486,000 after acquiring an additional 12,174 shares during the period. Finally, PDT Partners LLC lifted its stake in Astria Therapeutics by 90.3% in the second quarter. PDT Partners LLC now owns 54,642 shares of the biotechnology company's stock worth $293,000 after acquiring an additional 25,935 shares during the period. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.